Market Overview

Antibe Therapeutics Inc., Safe Pain and Inflammation Medicine, CEO Clip Video

Share:

Vancouver, British Columbia--(Newsfile Corp. - September 13, 2017) - Dan Legault, CEO of Antibe Therapeutics Inc., on the company's best-in-class pain/inflammation and regenerative medicine divisions.

If you cannot view the video above, please visit:
http://www.b-tv.com/antibe-therapeutics-ceo-clip-90sec/

Antibe Therapeutics Inc. is being featured on CBC's Documentary Channel Sept. 18— Oct. 1, 2017 Monday through Friday, throughout the day and evenings.

Antibe Therapeutics Inc. (TSXV: ATE):

Antibe is a diversified biotechnology company with two best-in-class divisions in pain/inflammation and regenerative medicine. Its blockbuster drug platform has a lead asset in Phase 2, and the combined pipeline is targeting a global market opportunity in excess of $20 billion. Antibe's commercial division in regenerative medicine is on a global growth trajectory in the dental biologics market.

www.antibethera.com

About CEO Clips:

CEO Clips is the largest library of publicly traded company CEO videos in the US and Canada.  These 90 second video profiles broadcast on national TV and are distributed online on top financial portals including: Thomson Reuters, BNN.ca, and Stockhouse.com.  They are also disseminated via a video news release to several financial portals including Globe Investor, OTC Markets, TMX Money, and The National Post.

BTV — Business Television/CEO Clip Contact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com

>

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com